31例血管免疫母T细胞淋巴瘤临床分析

王彦艳; 吕艳芳; ZHAOShu; 庄永志

doi:10.3969/j.issn.1000-8179.20140489

31例血管免疫母T细胞淋巴瘤临床分析

Clinical features of 31 cases of angioimmunoblastic T-cell lymphoma

摘要

摘要:
目的探讨血管免疫母T细胞淋巴瘤（AITL）的发病情况、临床特点、诊断及治疗。
方法回顾性分析哈尔滨医科大学附属肿瘤医院1995年1月至2008年1月哈尔滨医科大学附属肿瘤医院收治的31例AITL患者的临床及随访资料，分析其发病情况、临床特征、诊断及不同治疗方案对有效率的影响。
结果 31例完全缓解率（CR）为54.8%，部分缓解率为（PR）16.1%，总有效率为（70.9%），中位生存时间27.3个月，5年总生存率为35%，CHOP（CTX VCR ADM PDN）组和COP（CTX VCR PDN）组有效率分别为76.5%和75%，无显著差异（P > 0.05）。
结论 AITL临床表现多样且无特异性，其首发部位广泛，化疗对本病有效率较高。COP化疗方案与CHOP疗效相似且不良反应小，值得推荐。

Abstract:
Objective To study the incidence, clinical features, diagnosis, and treatment of angioimmunoblastic T-cell Lymphoma (AITL).
Methods We retrospectively analyzed the clinical data of 31 patients with AITL treated in the tumor hospital of Harbin Medical University between January 1995 and January 2008. We also analyzed the incidence, clinical features, diagnosis, and treatment of AITL.
Results The complete response rate and partial response rate of the entire group were 54.8% and 16.1%, respectively. The overall response rate was 70.9%, and the median survival time was 27.3 months. The five-year survival rate of the entire group was 35%. The response rate was 76.5% in the CHOP group and 75% in the COP group. No significant differences were detected between two groups (P > 0.05).
Conclusions The symptoms and signs of ATIL differ in different sites. The COP and CHOP regimens have similar efficacy and tolerable side effects.

HTML全文

参考文献(15)

施引文献

资源附件(0)